INDOCO REMEDIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 337.7 INR | +1.90% |
|
+2.77% | -14.55% |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 18,642 | 19,388 | 26,498 | 34,745 | 29,972 | 31,130 | - | - |
| Enterprise Value (EV) 1 | 18,642 | 19,388 | 26,498 | 34,745 | 29,972 | 31,130 | 31,130 | 31,130 |
| P/E ratio | -653 x | 80.3 x | 28.5 x | 22.4 x | 21.1 x | 28.6 x | 18.9 x | 15.2 x |
| Yield | 0.15% | 0.14% | 0.52% | 0.6% | 0.69% | 0.59% | 0.69% | 0.82% |
| Capitalization / Revenue | 1.92 x | 1.75 x | 2.13 x | 2.26 x | 1.8 x | 1.71 x | 1.54 x | 1.39 x |
| EV / Revenue | 1.92 x | 1.75 x | 2.13 x | 2.26 x | 1.8 x | 1.71 x | 1.54 x | 1.39 x |
| EV / EBITDA | 22.5 x | 20.1 x | 11.8 x | 10.6 x | 10.5 x | 12 x | 9.39 x | 8 x |
| EV / FCF | 65.7 x | 30.1 x | 493 x | 71.6 x | -105 x | -92 x | 36.4 x | 25.2 x |
| FCF Yield | 1.52% | 3.32% | 0.2% | 1.4% | -0.95% | -1.09% | 2.75% | 3.97% |
| Price to Book | 2.82 x | 2.85 x | 3.45 x | 3.84 x | 2.91 x | 2.79 x | 2.46 x | 2.15 x |
| Nbr of stocks (in thousands) | 92,150 | 92,150 | 92,150 | 92,150 | 92,150 | 92,182 | - | - |
| Reference price 2 | 202.3 | 210.4 | 287.6 | 377.0 | 325.2 | 337.7 | 337.7 | 337.7 |
| Announcement Date | 5/29/19 | 6/24/20 | 5/25/21 | 5/17/22 | 5/23/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Marzo | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9,684 | 11,066 | 12,415 | 15,408 | 16,686 | 18,192 | 20,177 | 22,437 |
| EBITDA 1 | 828 | 966 | 2,243 | 3,273 | 2,861 | 2,600 | 3,316 | 3,893 |
| EBIT 1 | 112.3 | 548.3 | 1,511 | 2,507 | 2,155 | 1,764 | 2,476 | 3,006 |
| Operating Margin | 1.16% | 4.95% | 12.17% | 16.27% | 12.91% | 9.7% | 12.27% | 13.4% |
| Earnings before Tax (EBT) 1 | -93.1 | 285.8 | 1,320 | 2,366 | 1,928 | 1,445 | 2,202 | 2,731 |
| Net income 1 | -29 | 241.2 | 930.5 | 1,548 | 1,422 | 1,073 | 1,649 | 2,046 |
| Net margin | -0.3% | 2.18% | 7.49% | 10.05% | 8.53% | 5.9% | 8.17% | 9.12% |
| EPS 2 | -0.3100 | 2.620 | 10.10 | 16.80 | 15.42 | 11.82 | 17.88 | 22.20 |
| Free Cash Flow 1 | 283.6 | 643.8 | 53.7 | 485.1 | -284.3 | -338.5 | 855.3 | 1,236 |
| FCF margin | 2.93% | 5.82% | 0.43% | 3.15% | -1.7% | -1.86% | 4.24% | 5.51% |
| FCF Conversion (EBITDA) | 34.25% | 66.65% | 2.39% | 14.82% | - | - | 25.8% | 31.76% |
| FCF Conversion (Net income) | - | 266.92% | 5.77% | 31.33% | - | - | 51.86% | 60.44% |
| Dividend per Share 2 | 0.3000 | 0.3000 | 1.500 | 2.250 | 2.250 | 2.000 | 2.325 | 2.775 |
| Announcement Date | 5/29/19 | 6/24/20 | 5/25/21 | 5/17/22 | 5/23/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4,091 | 4,082 | 4,330 | 3,992 | 4,282 | 4,265 | 4,512 | 4,790 | 4,680 |
| EBITDA 1 | 805.4 | 714.5 | 878.5 | 620.4 | 647.6 | 611.7 | 826.7 | 797.8 | 677 |
| EBIT | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | 597.5 | 483.5 | 673 | 382.2 | 389.3 | - | - | - | - |
| Net income 1 | 404.5 | 385.7 | 497.3 | 281.4 | 258.1 | 243.9 | 456 | 414.3 | 340 |
| Net margin | 9.89% | 9.45% | 11.48% | 7.05% | 6.03% | 5.72% | 10.11% | 8.65% | 7.27% |
| EPS 2 | - | - | 5.400 | 3.050 | - | 2.620 | 4.100 | 3.800 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/17/22 | 8/9/22 | 11/10/22 | 1/24/23 | 5/23/23 | 7/25/23 | - | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 284 | 644 | 53.7 | 485 | -284 | -339 | 855 | 1,236 |
| ROE (net income / shareholders' equity) | -0.43% | 3.6% | 12.8% | 18.5% | 14.7% | 9.98% | 13.7% | 14.9% |
| ROA (Net income/ Total Assets) | - | - | 7.19% | - | - | - | - | - |
| Assets 1 | - | - | 12,933 | - | - | - | - | - |
| Book Value Per Share 2 | 71.70 | 73.70 | 83.40 | 98.20 | 112.0 | 121.0 | 137.0 | 157.0 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 969 | 585 | 769 | 1,253 | 2,073 | 1,510 | 1,361 | 1,323 |
| Capex / Sales | 10.01% | 5.28% | 6.19% | 8.13% | 12.42% | 8.3% | 6.75% | 5.9% |
| Announcement Date | 5/29/19 | 6/24/20 | 5/25/21 | 5/17/22 | 5/23/23 | - | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
337.7
INR
Average target price
395.2
INR
Spread / Average Target
+17.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.55% | 373M | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
- Stock Market
- Equities
- INDOCO Stock
- Financials Indoco Remedies Limited
